High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort
Source
Journal of the International AIDS Society
Authors
B.G. MirembeD. DonnellM. KrowsZ. ZwaneE. BukusiR. PanchiaC. LouwN. MwelaseP. SelepeM. SenneL. NaidooR. ChihanaM. KasaroH. Nuwagaba-BiribonwohaP. KotzeK. GillP. MacDonaldA. Van HeerdenS. BosmanM. JaggernathP. Du PreezA. WardR.P.H. PetersS. Delany-MoretlweS. PeacockR. JohnsonJ. CaucuttS. MorrisonG. WangM. GandhiJ. VellozaR. HeffronC. Celum
PUBLICATION YEAR:
2024
OUTPUT TYPE:
Journal Article
Print
HSRC Library: shelf number 9814781
handle
https://doi.org/10.14749/32361381
Adolescent girls and young women (AGYW) account for two-thirds of new HIV infections in Africa. African AGYW have had high uptake of oral HIV pre-exposure prophylaxis (PrEP) but low adherence, which might be improved by point-of-care adherence monitoring with tailored counselling. From August 2022 to July 2023, we conducted a PrEP demonstration project with sexually active AGYW ages 16รข??30 years from 20 sites in South Africa, Eswatini, Kenya, Malawi, Uganda and Zambia. Participants were offered oral tenofovir-based PrEP at enrolment and followed up at 1, 3 and 6 months. PrEP adherence was assessed by a point-of-care qualitative lateral flow urine tenofovir (TFV) assay indicating PrEP use in the prior 4 days, which accompanied real-time adherence counselling that incorporated urine TFV results when testing was available (70.8% of month 1, 35.3% of month 3 and 83.9% of month 6 visits). We estimated overall adherence, correcting for missing test results, and analysed the association of having received urine TFV results at month 1 or 3 with subsequent urine TFV test positivity, using modified Poisson regression.